[29-412-pm] Antibacterial, antiviral and antifungal agents 2/Vaccines and bioactive agents

[29-412-pm18] Development of live attenuated SARS-CoV-2 vaccine with combined substitutions and deletions responsible to attenuation

○Mie Suzuki¹, Shinya Okamura^1,2, Akiho Yoshida^1,2, Gis Tang¹, Yuka Koizumi¹, Mai Matsumoto¹, Suni Lee¹, Shiro Takekawa¹, Koichi Yamanishi¹, Hirotaka Ebina^1,2,3 (1. The research foundation for microbial diseases of osaka university, 2. Virus Vaccine group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, 3. The Research Institute for Microbial Diseases of Osaka University)